Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops
By Colin Kellaher
Shares of Ocuphire Pharma rose sharply in premarket trading Wednesday after the ophthalmic biopharmaceutical company and partner Viatris won U.S. Food and Drug Administration approval of their Ryzumvi eye drops.
Ocuphire and Viatris on Wednesday said the approval covers Ryzumvi for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents.
Ocuphire, based in Farmington Hills, Mich., last year inked a licensing agreement for the development and commercialization of Ryzumvi with FamyGen Life Sciences, which healthcare company Viatris acquired earlier this year.
Ocuphire and Viatris said they expect Ryzumvi to be commercially available in the U.S. in the first half of 2024.
Shares of Ocuphire, which closed Tuesday at $4.02, were recently up 9.5% to $4.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth